TY - JOUR
T1 - Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017
AU - Adult IPD Study Group
AU - Shimbashi, Reiko
AU - Suzuki, Motoi
AU - Chang, Bin
AU - Watanabe, Hiroshi
AU - Tanabe, Yoshinari
AU - Kuronuma, Koji
AU - Oshima, Kengo
AU - Maruyama, Takaya
AU - Takeda, Hiroaki
AU - Kasahara, Kei
AU - Fujita, Jiro
AU - Nishi, Junichiro
AU - Kubota, Tetsuya
AU - Tanaka-Taya, Keiko
AU - Matsui, Tamano
AU - Sunagawa, Tomimasa
AU - Oishi, Kazunori
N1 - Funding Information:
This work was supported by MHLW HA Program Grant Number JPMH20HA1005.
PY - 2020/10
Y1 - 2020/10
N2 - The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.
AB - The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.
UR - http://www.scopus.com/inward/record.url?scp=85091324461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091324461&partnerID=8YFLogxK
U2 - 10.3201/eid2610.191531
DO - 10.3201/eid2610.191531
M3 - Review article
C2 - 32946721
AN - SCOPUS:85091324461
VL - 26
SP - 2378
EP - 2386
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
SN - 1080-6040
IS - 10
ER -